Capsida Biotherapeutics Achieves Significant Milestone
Capsida Biotherapeutics is making substantial strides in the world of gene therapy. The company proudly announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its lead investigational gene therapy, CAP-002. This therapy targets developmental and epileptic encephalopathy (DEE) associated with mutations in the STXBP1 gene. With this designation, Capsida is on track to make a significant impact in treating this rare condition.
What is CAP-002?
Innovative Gene Therapy Approach
CAP-002 represents a groundbreaking advancement in gene therapy. This unique treatment is designed to be administered intravenously, utilizing Capsida's proprietary engineered capsids. These capsids are specifically created to deliver the STXBP1 protein across the entire brain while minimizing exposure to non-target organs, particularly the liver. Currently, CAP-002 is undergoing IND-enabling studies to pave the way for clinical trials anticipated to commence in the first half of 2025.
Importance of STXBP1 Protein
The STXBP1 protein plays a crucial role in neuronal function, being present in every neuron and vital for proper neurotransmission. Mutations in the STXBP1 gene can lead to several severe symptoms, including treatment-resistant seizures, developmental delays, and serious cognitive impairments. The ongoing preclinical studies have shown great promise, indicating that gene therapy could correct these issues effectively. These findings are based on collaborations with leading researchers and specialized disease models.
The Impact of Orphan Drug Designation
Receiving Orphan Drug Designation is more than just a regulatory milestone; it represents a beacon of hope for patients and families affected by STXBP1 developmental and epileptic encephalopathy. This designation not only facilitates a closer collaboration with the FDA but also offers various incentives, including potential tax breaks for clinical trials and market exclusivity upon approval.
About STXBP1 Developmental and Epileptic Encephalopathy
Globally, STXBP1 developmental and epileptic encephalopathy is estimated to affect one in 26,000 children. The staggering impact of this disorder includes severe developmental disabilities and a lack of approved treatments, making the advancement of CAP-002 a pivotal step forward in the treatment landscape.
About Capsida Biotherapeutics
Founded with an innovative spirit, Capsida Biotherapeutics is dedicated to providing transformative gene therapies for a range of neurological disorders. The company’s CNS pipeline is designed to address both rare and prevalent conditions through carefully crafted therapies. Their approach not only targets specific diseases but also aims to achieve a broad-spectrum effectiveness in various age groups.
Looking Ahead
Capsida's commitment to advancing gene therapy is underscored by its plans to submit an IND for CAP-002 in the near future. Swati Tole, M.D., the Chief Medical Officer at Capsida, emphasized the company's vision to bring lasting change to those living with high unmet medical needs, particularly in the field of STXBP1 disorders. As they move closer to their clinical trial phases, the anticipation of a first-in-class treatment brings hope to many.
Frequently Asked Questions
What is CAP-002?
CAP-002 is an investigational gene therapy developed by Capsida Biotherapeutics aimed at treating developmental and epileptic encephalopathy due to mutations in the STXBP1 gene.
What does Orphan Drug Designation mean?
Orphan Drug Designation is granted by the FDA to encourage the development of therapies for rare diseases, providing various incentives to speed up the treatment process.
Where does Capsida stand with CAP-002's development?
Capsida is currently conducting IND-enabling studies with plans to file for an Investigational New Drug application in the first half of 2025.
What symptoms are associated with STXBP1 mutations?
Symptoms include treatment-resistant seizures, severe developmental delay, intellectual disabilities, motor abnormalities, and a risk of sudden unexpected death in epilepsy (SUDEP).
What is Capsida Biotherapeutics’ mission?
Capsida Biotherapeutics aims to develop innovative gene therapies for neurological disorders, significantly impacting the lives of patients with rare diseases.
